Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HYP082
MIFTS: 41

Hypopharynx Cancer

Categories: Rare diseases, Cancer diseases, Gastrointestinal diseases, Bone diseases, Oral diseases
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Hypopharynx Cancer

About this section

MalaCards integrated aliases for Hypopharynx Cancer:

Name: Hypopharynx Cancer 12 15
Hypopharyngeal Cancer 12 53 55 73
Hypopharyngeal Neoplasms 44 73
Malignant Neoplasm of Ill-Defined Sites Within the Lip and Oral Cavity 12
Malignant Neoplasm of Other Specified Sites of Hypopharynx 12
Malignant Neoplasm of Other Specified Hypopharyngeal Site 12
Malignant Neoplasm of Posterior Hypopharyngeal Wall 12
Malignant Neoplasm of Posterior Wall of Hypopharynx 12
Malignant Tumor of Posterior Wall of Hypopharynx 12
Malignant Neoplasm of Hypopharynx 12
Malignant Tumour of Hypopharynx 12
Malignant Hypopharyngeal Tumor 12
Malignant Tumor of Hypopharynx 12
Hypopharyngeal Carcinoma 73

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Bone diseases Oral diseases
See all MalaCards categories (disease lists)
ICD10: 33


Sources

Summaries for Hypopharynx Cancer

About this section
Disease Ontology : 12 A pharynx cancer that is located in the hypopharynx.

MalaCards based summary : Hypopharynx Cancer, also known as hypopharyngeal cancer, is related to postcricoid region cancer and aryepiglottic fold cancer. An important gene associated with Hypopharynx Cancer is MIR489 (MicroRNA 489
Hypopharyngeal squamous cell carcinoma (HSCC) is an aggressive malignancy with one of the worst prognoses among all head and neck cancers. It was shown that miR-489 inhibited cell growth in all head and neck cancer cell lines examined. The gene PTPN11 coding for a cytoplasmic protein tyrosine phosphatase containing two Src Homology 2 domains was identified as a miR-489-targeted gene. Knockdown of PTPN11 resulted in the inhibition of cell proliferation in head and neck SCC cells. Identification of the tumour-suppressive miRNA miR-489 and its target, PTPN11, might provide new insights into the underlying molecular mechanisms of HSCC.). The drugs Nicotine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include the hypopharynx, lung and liver, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Sources

Related Diseases for Hypopharynx Cancer

About this section

Diseases related to Hypopharynx Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 13)
# Related Disease Score Top Affiliating Genes
1 postcricoid region cancer 10.1
2 aryepiglottic fold cancer 10.1
3 gum cancer 10.0 MMP8 SMUG1
4 lipid pneumonia 9.9 MMP8 SMUG1
5 supraglottis cancer 9.9 CD6 SMUG1
6 pharyngitis 9.8
7 aging 9.7
8 laryngitis 9.7
9 laryngeal cleft 9.7
10 respiratory system cancer 9.7 MET SMUG1
11 anus cancer 9.7 CD6 SMUG1
12 oropharynx cancer 9.5 CD6 MMP8 SMUG1
13 pharynx cancer 9.5 CD6 MMP8 SMUG1

Comorbidity relations with Hypopharynx Cancer via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Hypopharynx Cancer:



Diseases related to Hypopharynx Cancer
Sources

Symptoms & Phenotypes for Hypopharynx Cancer

About this section

GenomeRNAi Phenotypes related to Hypopharynx Cancer according to GeneCards Suite gene sharing:

26 (show all 34)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-111 9.91 CNDP2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 9.91 NME1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.91 CNDP2
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-14 9.91 CNDP2
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.91 CNDP2
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.91 CNDP2
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.91 CNDP2 NME1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 9.91 MSMO1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 9.91 MSMO1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.91 MSMO1
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.91 CNDP2 MSMO1 NME1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 9.91 CNDP2
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.91 CNDP2
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-75 9.91 NME1
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 9.91 CNDP2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.64 MMP8
17 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.64 MSMO1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.64 MSMO1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.64 MSMO1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.64 GNB1L
21 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.64 MMP8
22 Increased shRNA abundance (Z-score > 2) GR00366-A-195 9.64 GNB1L
23 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.64 GNB1L MMP8 MSMO1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.64 MMP8
25 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.64 MSMO1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-41 9.64 MMP8
27 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.64 GNB1L
28 Increased shRNA abundance (Z-score > 2) GR00366-A-5 9.64 MMP8
29 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.64 MMP8
30 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.64 MSMO1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.64 MMP8
32 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.64 GNB1L
33 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.64 GNB1L
34 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.64 MMP8
Sources

Drugs & Therapeutics for Hypopharynx Cancer

About this section

Drugs for Hypopharynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 286)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
2
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
3
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
4 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
5 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3
6 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
9 Central Nervous System Stimulants Phase 4,Phase 3,Not Applicable
10 Cholinergic Agents Phase 4,Phase 2,Phase 3,Not Applicable
11 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
12 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2
13 Nicotinic Agonists Phase 4,Not Applicable
14 Dopamine Agents Phase 4,Phase 2
15 Dopamine Uptake Inhibitors Phase 4,Phase 2
16 Antidepressive Agents Phase 4,Phase 3,Phase 2,Not Applicable
17 Antidepressive Agents, Second-Generation Phase 4,Phase 2
18 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
19
Tegafur Approved, Investigational Phase 3,Phase 2 17902-23-7 5386
20
Cisplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 15663-27-1 84093 441203 2767
21
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
22
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 33069-62-4 36314
23
Cetuximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 205923-56-4 56842117 2333
24
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
25
Epinephrine Approved, Vet_approved Phase 3,Phase 2 51-43-4 5816
26
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
27
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
28
Racepinephrine Approved Phase 3,Phase 2 329-65-7 838
29
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
30
Isotretinoin Approved Phase 3,Phase 2 4759-48-2 5538 5282379
31
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
32
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
33
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
34
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
35
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
36
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
37
Pilocarpine Approved, Investigational Phase 2, Phase 3 54-71-7, 92-13-7 5910
38
Histamine Approved, Investigational Phase 3,Not Applicable 75614-87-8, 51-45-6 774
39
Doxepin Approved, Investigational Phase 3,Not Applicable 1668-19-5 667477 667468
40
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
41
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
42
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
43
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
44
Tocopherol Approved, Investigational, Nutraceutical Phase 3 1406-66-2 14986
45
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
46
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
47 Kava Approved, Investigational, Nutraceutical Phase 3,Phase 2 9000-38-8
48 Porfiromycin Investigational Phase 3 801-52-5
49 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
50 Analgesics Phase 3,Phase 1,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 350)
# Name Status NCT ID Phase Drugs
1 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
2 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
3 Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced Xerostomia Unknown status NCT00081029 Phase 3
4 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
5 Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Advanced Cancer of the Oropharynx or Hypopharynx Unknown status NCT00003627 Phase 3 cisplatin;fluorouracil
6 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
7 S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil
8 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
9 Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma Completed NCT00169182 Phase 3 DOCETAXEL
10 Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
11 Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Completed NCT00158652 Phase 3 5FU, Paraplatin
12 Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00008398 Phase 3
13 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
14 Combination Chemotherapy Plus Radiation Therapy To Preserve the Larynx in Patients With Cancer of the Hypopharynx or Larynx Completed NCT00002839 Phase 3 cisplatin;fluorouracil
15 Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients Completed NCT01439724 Phase 3
16 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
17 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
18 Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002507 Phase 3 mitomycin C;porfiromycin
19 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
20 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
21 Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx Completed NCT00004234 Phase 3
22 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
23 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
24 Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00021125 Phase 3
25 Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer Completed NCT00004917 Phase 3 cisplatin
26 Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT00771641 Phase 3
27 Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002888 Phase 3 cisplatin;fluorouracil;paclitaxel
28 Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00003809 Phase 3 cisplatin
29 Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery Completed NCT00002670 Phase 3 chemotherapy;cisplatin
30 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3 fluorouracil;leucovorin calcium;methotrexate;vincristine sulfate
31 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
32 Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Completed NCT00820248 Phase 3 cisplatin
33 Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00608205 Phase 3 cisplatin;fluorouracil
34 Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial) Completed NCT00095875 Phase 3 carboplatin;cisplatin;docetaxel;fluorouracil
35 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3 methotrexate;paclitaxel
36 Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00003328 Phase 3 porfiromycin
37 Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002654 Phase 3 chemotherapy;cisplatin
38 High-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002555 Phase 3 cisplatin
39 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003888 Phase 3 cisplatin;docetaxel;fluorouracil
40 Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer Completed NCT00006481 Phase 3 Biafine cream
41 Surgery and Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer That Can Be Removed During Surgery Completed NCT00003576 Phase 3 cisplatin;fluorouracil
42 Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00054561 Phase 3 isotretinoin
43 Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection Recruiting NCT02918955 Phase 3 Chemotherapy (Cisplatin)
44 Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer Recruiting NCT01772706 Phase 3
45 Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck Recruiting NCT02236936 Phase 3 Cisplatin
46 IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC Active, not recruiting NCT00158678 Phase 3 concomitant cisplatin
47 Acupuncture in Treating Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer Active, not recruiting NCT01141231 Phase 3
48 Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Active, not recruiting NCT01810913 Phase 2, Phase 3 cisplatin;docetaxel
49 Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer Active, not recruiting NCT00265941 Phase 3 cetuximab;cisplatin
50 Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer Active, not recruiting NCT00047008 Phase 3 cisplatin

Search NIH Clinical Center for Hypopharynx Cancer

Cochrane evidence based reviews: hypopharyngeal neoplasms

Sources

Genetic Tests for Hypopharynx Cancer

About this section
Sources

Anatomical Context for Hypopharynx Cancer

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Hypopharynx Cancer:

19
The Hypopharynx

MalaCards organs/tissues related to Hypopharynx Cancer:

41
Lung, Liver, Brain, Lymph Node, Breast, Skin, Thyroid
Sources

Publications for Hypopharynx Cancer

About this section

Articles related to Hypopharynx Cancer:

(show all 50)
# Title Authors Year
1
Association of eIF4E and SPARC Expression with Lymphangiogenesis and Lymph Node Metastasis in Hypopharyngeal Cancer. ( 29374693 )
2018
2
Boerhaave syndrome due to hypopharyngeal stenosis associated with chemoradiotherapy for hypopharyngeal cancer: a case report. ( 29884971 )
2018
3
Trends in treatment, incidence and survival of hypopharynx cancer: a 20-year population-based study in the Netherlands. ( 29080963 )
2018
4
Sequential four-drug chemotherapy and intensity-modulated radiotherapy for larynx preservation in resectable advanced larynx and hypopharynx cancer: A pilot study. ( 27825651 )
2017
5
The impact of elevated C-reactive protein level on the prognosis for oro-hypopharynx cancer patients treated with radiotherapy. ( 29259311 )
2017
6
Persistent Tracheostomy after Organ Preservation Protocol in Patients Treated for Larynx and Hypopharynx Cancer. ( 29018502 )
2017
7
Downregulation of Calcium-Binding Protein S100A9 Inhibits Hypopharyngeal Cancer Cell Proliferation and Invasion Ability Through Inactivation of NF-I_B Signaling. ( 28276321 )
2017
8
A case of adult congenital laryngeal cleft asymptomatic until hypopharynx cancer treatment. ( 28943051 )
2017
9
Down syndrome critical region 1 positively correlates with angiogenesis in hypopharyngeal cancer. ( 27922696 )
2017
10
Association of the upregulated expression of focal adhesion kinase with poor prognosis and tumor dissemination in hypopharyngeal cancer. ( 27061113 )
2016
11
CD271 regulates the proliferation and motility of hypopharyngeal cancer cells. ( 27469492 )
2016
12
Elevated AEG-1 expression in macrophages promotes hypopharyngeal cancer invasion through the STAT3-MMP-9 signaling pathway. ( 27793010 )
2016
13
Intensity-modulated radiotherapy for laryngeal and hypopharyngeal cancer : Minimization of late dysphagia without jeopardizing tumor control. ( 25367098 )
2014
14
Comparative planning of flattening-filter-free and flat beam IMRT for hypopharynx cancer as a function of beam and segment number. ( 24722621 )
2014
15
HPV: a factor in organ preservation for locally advanced larynx and hypopharynx cancer? ( 24119488 )
2014
16
Routine endoscopy for esophageal cancer is suggestive for patients with oral, oropharyngeal and hypopharyngeal cancer. ( 23977217 )
2013
17
CD44 as a molecular marker to screen cancer stem cells in hypopharyngeal cancer. ( 23837451 )
2013
18
Potential biomarkers for paclitaxel sensitivity in hypopharynx cancer cell. ( 24294361 )
2013
19
CD271 defines a stem cell-like population in hypopharyngeal cancer. ( 23626764 )
2013
20
Role of centromere protein H and Ki67 in relapse-free survival of patients after primary surgery for hypopharyngeal cancer. ( 22631655 )
2012
21
Management of oropharyngeal Dysphagia in laryngeal and hypopharyngeal cancer. ( 23346112 )
2012
22
Radiochemotherapy versus surgery plus radio(chemo)therapy for stage T3/T4 larynx and hypopharynx cancer - results of a matched-pair analysis. ( 21726998 )
2011
23
Videostroboscopic and morphological aspects of voice disturbances in patients with larynx atrophy and coexisting hypopharynx cancer. ( 22252761 )
2011
24
Impact of combination therapy on disease free survival in hypopharynx cancer. ( 21340251 )
2010
25
Role of human papillomavirus in the clinical and histopathologic features of laryngeal and hypopharyngeal cancers. ( 19344621 )
2009
26
Cyclooxygenase 2 promoter-based replication-selective adenoviral vector for hypopharyngeal cancer. ( 19289707 )
2009
27
Identification of matrix metalloproteinase-9 as an independent prognostic marker in laryngeal and hypopharyngeal cancer with opposite correlations to adhesion/growth-regulatory galectins-1 and -7. ( 19148478 )
2009
28
Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. ( 19179556 )
2009
29
The importance of pre-epiglottis space invasion in the treatment planning of larynx and hypopharynx cancer. ( 18392505 )
2008
30
[Expression of survivin and its correlation with p53 and bcl-2 expression in laryngeal and hypopharyngeal cancer]. ( 18595518 )
2008
31
Morphological aspect of voice disturbances of aged persons coexisting hypopharynx cancer. ( 17951171 )
2007
32
Retropharyngeal nodes in hypopharynx cancer on positron emission tomography. ( 17290070 )
2007
33
Hypermethylation, risk factors, clinical characteristics, and survival in 235 patients with laryngeal and hypopharyngeal cancers. ( 17786935 )
2007
34
Galectin 7 (p53-induced gene 1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer. ( 16788763 )
2006
35
[Expression of CD44 and nm23-H1 protein in the primary and metastatic lymph node lesions in supraglottic and hypopharyngeal cancer]. ( 16848180 )
2006
36
The influence of RBE variations in a clinical proton treatment plan for a hypopharynx cancer. ( 15930601 )
2005
37
Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer. ( 15743695 )
2005
38
The syndrome of inappropriate antidiuretic hormone secretion associated with chemotherapy for hypopharyngeal cancer. ( 15513517 )
2004
39
Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis. ( 14676830 )
2004
40
The clinicopathological significance of p53 and p21 expression in squamous cell carcinoma of hypopharyngeal cancer. ( 14607337 )
2003
41
Occupation and larynx and hypopharynx cancer: an international case-control study in France, Italy, Spain, and Switzerland. ( 12814199 )
2003
42
Occupation and larynx and hypopharynx cancer: a job-exposure matrix approach in an international case-control study in France, Italy, Spain and Switzerland. ( 12814200 )
2003
43
Intratumor microvessel density in biopsy specimens predicts local response of hypopharyngeal cancer to radiotherapy. ( 14769838 )
2003
44
Role of multimodal treatment in oropharynx, larynx, and hypopharynx cancer. ( 11291134 )
2001
45
Paraneoplastic syndromes in patients with laryngeal and hypopharyngeal cancers. ( 10651424 )
2000
46
p27 expression correlates with prognosis in patients with hypopharyngeal cancer. ( 10650784 )
1999
47
Detection of the proto-oncogene eIF4E in larynx and hypopharynx cancers. ( 10037284 )
1999
48
Endoscopic treatment of supraglottic and hypopharynx cancer. ( 8295459 )
1994
49
Larynx preservation with combined chemotherapy and radiation therapy in advanced hypopharynx cancer. ( 8028939 )
1994
50
SURGICAL TREATMENT OF LARYNX AND HYPOPHARYNX CANCER. ( 14090428 )
1964
Sources

Variations for Hypopharynx Cancer

About this section
Sources

Expression for Hypopharynx Cancer

About this section
Search GEO for disease gene expression data for Hypopharynx Cancer.
Sources

Pathways for Hypopharynx Cancer

About this section
Sources

GO Terms for Hypopharynx Cancer

About this section
Sources

Sources for Hypopharynx Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....